13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001697013
Total reported value
$1.9B
$1.9B
56 檔
20.8%
The Q1 2025 SEC filing reveals that Eversept Partners, LP held a total portfolio value of $1.9B, covering 56 public equity positions.
In Q1 2025, Eversept Partners, LP displayed an active expansion posture, initiating 56 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including NTRA, GSK, QQQ) accounted for 20.8% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | Stock-Healthcare | 12.83% | -1.58% | +1.93% | |
| 2 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 10.32% | -3.89% | -28.36% | |
| 3 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 7.03% | -3.49% | -39.28% | |
| 4 | HCA | Hca Healthcare Inc | Stock-Healthcare | 5.35% | +0.01% | -13.26% | |
| 5 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 5.26% | -0.38% | +1126.64% | |
| 6 | VERA | Vera Therapeutics Inc | Stock-Other | 4.63% | +0.32% | +18.67% | |
| 7 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 4.37% | -3.67% | EXIT | |
| 8 | RVTY | Revvity Inc | Stock-Healthcare | 3.21% | +0.09% | -23.80% | |
| 9 | HQY | Healthequity Inc | Stock-Healthcare | 3.16% | -0.23% | EXIT | |
| 10 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 3.02% | — | -36.66% | |
| 11 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.69% | +0.37% | NEW | |
| 12 | CYH | Community Health Systems Inc | Stock-Other | 2.32% | +0.01% | +199.19% | |
| 13 | ZIMV | Zimvie Inc | Stock-Other | 2.28% | — | +0.42% | |
| 14 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 2.20% | — | -37.08% | |
| 15 | PCVX | Vaxcyte Inc | Stock-Other | 2.14% | -0.93% | +336.62% | |
| 16 | BRKR | Bruker CORP | Stock-Healthcare | 2.12% | +0.35% | +112.49% | |
| 17 | CNC | Centene CORP | Stock-Healthcare | 2.10% | -0.19% | EXIT | |
| 18 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.89% | +0.05% | +76.63% | |
| 19 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.88% | — | — | |
| 20 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.80% | -0.17% | +31.54% | |
| 21 | TECH | Bio-techne CORP | Stock-Healthcare | 1.67% | -0.28% | -6.41% | |
| 22 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.65% | -0.56% | +9.70% | |
| 23 | GKOS | Glaukos CORP | Stock-Healthcare | 1.59% | -0.13% | — | |
| 24 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.58% | +0.23% | +140.53% | |
| 25 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.49% | +1.50% | +66.48% | |
| 26 | GMED | Globus Medical Inc - A | Stock-Healthcare | 1.43% | — | — | |
| 27 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.28% | +0.46% | -3.24% | |
| 28 | ALGN | Align Technology Inc | Stock-Healthcare | 0.80% | — | — | |
| 29 | TFX | Teleflex Inc | Stock-Healthcare | 0.79% | — | -8.27% | |
| 30 | MOH | Molina Healthcare Inc | Stock-Healthcare | 0.79% | +0.73% | — | |
| 31 | HUM | Humana Inc | Stock-Healthcare | 0.75% | +0.64% | NEW | |
| 32 | ELV | Elevance Health Inc | Stock-Healthcare | 0.69% | — | -46.20% | |
| 33 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.58% | — | +2.03% | |
| 34 | GOSS | Gossamer Bio Inc | Stock-Other | 0.44% | — | -21.73% | |
| 35 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.36% | — | +158.91% | |
| 36 | MNKD | Mannkind CORP | Stock-Other | 0.36% | — | -23.41% | |
| 37 | ✓ | Merus N V | Stock-Other | 0.30% | — | +3.03% | |
| 38 | RGEN | Repligen CORP | Stock-Healthcare | 0.24% | -0.65% | -65.87% | |
| 39 | NVAX | Novavax Inc | Stock-Healthcare | 0.24% | — | — | |
| 40 | LQDA | Liquidia CORP | Stock-Other | 0.23% | +0.42% | -73.66% | |
| 41 | FTRE | Fortrea Holdings Inc | Stock-Healthcare | 0.22% | — | -27.00% | |
| 42 | ETNBGBP | 89bio Inc | Stock-Other | 0.22% | — | — | |
| 43 | MRVI | Maravai Lifesciences Hldgs-a | Stock-Other | 0.21% | — | — | |
| 44 | AVTR | Avantor Inc | Stock-Healthcare | 0.20% | -1.23% | EXIT | |
| 45 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.19% | -0.40% | EXIT | |
| 46 | IFRX | InflaRx N.V. | Stock-Other | 0.17% | +0.07% | +240.33% | |
| 47 | ✓ | Amarin Corp PLC | Stock-Other | 0.15% | — | +124.13% | |
| 48 | STRO | Sutro Biopharma, Inc. | Stock-Other | 0.15% | — | +230.10% | |
| 49 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.13% | — | — | |
| 50 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.10% | +0.05% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | — | NEW | New buy |
| 2 | GSK | Gsk Plc-spon Adr | — | NEW | New buy |
| 3 | QQQ | Invesco Qqq Trust Series 1 | — | NEW | New buy |
| 4 | HCA | Hca Healthcare Inc | — | NEW | New buy |
| 5 | SNDX | Syndax Pharmaceuticals Inc | — | NEW | New buy |
| 6 | VERA | Vera Therapeutics Inc | — | NEW | New buy |
| 7 | SPY | Ss Spdr S&p 500 ETF Trust-us | — | NEW | New buy |
| 8 | RVTY | Revvity Inc | — | NEW | New buy |
| 9 | HQY | Healthequity Inc | — | NEW | New buy |
| 10 | INSP | Inspire Medical Systems Inc | — | NEW | New buy |
| 11 | PTGX | Protagonist Therapeutics Inc | — | NEW | New buy |
| 12 | CYH | Community Health Systems Inc | — | NEW | New buy |
| 13 | ZIMV | Zimvie Inc | — | NEW | New buy |
| 14 | TEVA | Teva Pharmaceutical-sp Adr | — | NEW | New buy |
| 15 | PCVX | Vaxcyte Inc | — | NEW | New buy |
| 16 | BRKR | Bruker CORP | — | NEW | New buy |
| 17 | CNC | Centene CORP | — | NEW | New buy |
| 18 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 19 | NBIX | Neurocrine Biosciences Inc | — | NEW | New buy |
| 20 | UTHR | United Therapeutics CORP | — | NEW | New buy |
| 21 | TECH | Bio-techne CORP | — | NEW | New buy |
| 22 | BCRX | Biocryst Pharmaceuticals Inc | — | NEW | New buy |
| 23 | GKOS | Glaukos CORP | — | NEW | New buy |
| 24 | IONS | Ionis Pharmaceuticals Inc | — | NEW | New buy |
| 25 | TVTX | Travere Therapeutics Inc | — | NEW | New buy |
| 26 | GMED | Globus Medical Inc - A | — | NEW | New buy |
| 27 | CLDX | Celldex Therapeutics Inc | — | NEW | New buy |
| 28 | ALGN | Align Technology Inc | — | NEW | New buy |
| 29 | TFX | Teleflex Inc | — | NEW | New buy |
| 30 | MOH | Molina Healthcare Inc | — | NEW | New buy |
| 31 | HUM | Humana Inc | — | NEW | New buy |
| 32 | ELV | Elevance Health Inc | — | NEW | New buy |
| 33 | NAMS | NewAmsterdam Pharma Company N.V. | — | NEW | New buy |
| 34 | GOSS | Gossamer Bio Inc | — | NEW | New buy |
| 35 | ZBIO | Zenas Biopharma Inc | — | NEW | New buy |
| 36 | MNKD | Mannkind CORP | — | NEW | New buy |
| 37 | ✓ | Merus N V | — | NEW | New buy |
| 38 | RGEN | Repligen CORP | — | NEW | New buy |
| 39 | NVAX | Novavax Inc | — | NEW | New buy |
| 40 | LQDA | Liquidia CORP | — | NEW | New buy |
| 41 | FTRE | Fortrea Holdings Inc | — | NEW | New buy |
| 42 | ETNBGBP | 89bio Inc | — | NEW | New buy |
| 43 | MRVI | Maravai Lifesciences Hldgs-a | — | NEW | New buy |
| 44 | AVTR | Avantor Inc | — | NEW | New buy |
| 45 | ICLR | ICON Public Limited Company | — | NEW | New buy |
| 46 | IFRX | InflaRx N.V. | — | NEW | New buy |
| 47 | ✓ | Amarin Corp PLC | — | NEW | New buy |
| 48 | STRO | Sutro Biopharma, Inc. | — | NEW | New buy |
| 49 | 2662247D | Iteos Therapeutics Inc | — | NEW | New buy |
| 50 | KPTI | Karyopharm Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Eversept Partners, LP reported a total U.S. public equity portfolio value of $1.9B across 56 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
NTRA
市值: $126.4M
During Q1 2025, Eversept Partners, LP's top holdings by market value included NTRA (12.8%)、GSK (10.3%)、QQQ (7.0%). The largest single position, NTRA, represented 12.8% of total portfolio value.
In Q1 2025, Eversept Partners, LP made 56 total portfolio adjustments, initiating 56 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.